Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Mar 14, 2022 2:21pm
138 Views
Post# 34512499

RE:RE:RE:RE:Stifel brokerage location?

RE:RE:RE:RE:Stifel brokerage location?Well said Wofats.
All makes sense to me.

Love Cymbria/Edgepoint ... the old Trimark Guard back in 2008 ... shares in Cymbria started at $8 back then.  Went to listen to Krimbel speak at the Fairmount in TO at thier opening shareholder introductory conference.  They love to come to the party early!!!  That's what I love about them.

Also keep in mind that on the financing side - the longer we go, the more money that comes out of the investments and becomes cash/marketable secutities.

Hopefully we're adding increasing amounts of cashflow from operations as well.

Then you have each and every new ROW drug to provide a multipier effect on that drug's sales.

Sorry, don't mean to repeat myself (too much) but this is why I'm here.  I'm going to enjoy the multiplier effect of new ROW drugs one day.  We went from 0 to $240M in sales over 7 years and that's no small feat. 

Selling the company at roughly 5x sales one day is why I'm here.  That's why I don't care about the market valuation is today.  I care what a Big Pharma will eventually pay for the beast.
<< Previous
Bullboard Posts
Next >>